Patents by Inventor Alexander M. Klibanov

Alexander M. Klibanov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10646571
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 12, 2020
    Assignee: Eagle Biologics, Inc.
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Publication number: 20200093820
    Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In a preferred embodiment, a drug is modified to increase its lipophilicity. In some embodiments the modified drug is homogeneously dispersed within spherical microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and/or organic solvent insoluble. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 26, 2020
    Applicant: Collegium Pharmaceutical, Inc.
    Inventors: Roman V. RARIY, Alison B. FLEMING, Jane HIRSH, Alexander M. KLIBANOV
  • Patent number: 10525053
    Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In a preferred embodiment, a drug is modified to increase its lipophilicity. In some embodiments the modified drug is homogeneously dispersed within spherical microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and/or organic solvent insoluble. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: January 7, 2020
    Assignee: Collegium Pharmaceutical, Inc.
    Inventors: Roman V. Rariy, Alison B. Fleming, Jane Hirsh, Alexander M. Klibanov
  • Patent number: 10500317
    Abstract: Orthopedic and dental implants coated with an antibacterial coating and methods of making and using, are described herein. The implant can be coated with a hydrophobic, polycationic antibacterial polymer. The polymer can be covalently or non-covalently associated with the surface; however, in particular embodiments, the polymer is non-covalently associated with the surface. As shown in the examples below, clinical observations, digital radiography, and a battery of well-accepted ex vivo analytical methods show that the presence of a hydrophobic polycationic polymer coating, such as N,N-dodecyl,methyl-PEI coating on the surface of a metal implant, was effective in eliminating the clinical signs of infection in vivo in a large animal infection model. Moreover, the coated plates supported bone healing, and in fact decreased healing times, even in the presence of significant bacterial contamination compared to a control.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: December 10, 2019
    Assignees: Massachusetts Institute of Technology, The Trustees of the University of Pennsylvania
    Inventors: Thomas P. Schaer, Suzanne Stewart, Alexander M. Klibanov
  • Patent number: 10179172
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering water soluble organic dyes.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: January 15, 2019
    Assignee: Eagle Biologics, Inc.
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Publication number: 20180228831
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of polysaccharides and nucleic acids have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight polysaccharides and nucleic acids, and viscosity-lowering agents.
    Type: Application
    Filed: September 30, 2015
    Publication date: August 16, 2018
    Inventors: Alyssa M. LARSON, Kevin LOVE, Alisha K. WEIGHT, Alan CRANE, Robert S. LANGER, Alexander M. KLIBANOV
  • Publication number: 20180177875
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.
    Type: Application
    Filed: February 23, 2018
    Publication date: June 28, 2018
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Publication number: 20180177876
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.
    Type: Application
    Filed: February 23, 2018
    Publication date: June 28, 2018
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Publication number: 20180153997
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 7, 2018
    Inventors: Alyssa M. Larson, Alisha K. Weight, Kevin Love, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Publication number: 20180085463
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.
    Type: Application
    Filed: November 10, 2017
    Publication date: March 29, 2018
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Patent number: 9925263
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: March 27, 2018
    Assignee: Eagle Biologics, Inc.
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Publication number: 20180078682
    Abstract: Orthopedic and dental implants coated with an antibacterial coating and methods of making and using, are described herein. The implant can be coated with a hydrophobic, polycationic antibacterial polymer. The polymer can be covalently or non-covalently associated with the surface; however, in particular embodiments, the polymer is non-covalently associated with the surface. As shown in the examples below, clinical observations, digital radiography, and a battery of well-accepted ex vivo analytical methods show that the presence of a hydrophobic polycationic polymer coating, such as N,N-dodecyl,methyl-PEI coating on the surface of a metal implant, was effective in eliminating the clinical signs of infection in vivo in a large animal infection model. Moreover, the coated plates supported bone healing, and in fact decreased healing times, even in the presence of significant bacterial contamination compared to a control.
    Type: Application
    Filed: November 16, 2017
    Publication date: March 22, 2018
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Thomas P. Schaer, Suzanne Stewart, Alexander M. Klibanov
  • Patent number: 9913905
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: March 13, 2018
    Assignee: EAGLE BIOLOGICS, INC.
    Inventors: Alyssa M. Larson, Alisha K. Weight, Kevin Love, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Publication number: 20180028529
    Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In a preferred embodiment, a drug is modified to increase its lipophilicity. In some embodiments the modified drug is homogeneously dispersed within spherical microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and/or organic solvent insoluble. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.
    Type: Application
    Filed: October 6, 2017
    Publication date: February 1, 2018
    Inventors: Roman V. Rariy, Alison B. Fleming, Jane Hirsh, Alexander M. Klibanov
  • Publication number: 20180028528
    Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble, but enzymatically degradable by enzymes present in the human gastrointestinal tract. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed.
    Type: Application
    Filed: October 5, 2017
    Publication date: February 1, 2018
    Inventors: Jane Hirsh, Alexander M. Klibanov, Timothy M. Swager, Stephen L. Buchwald, Whe Yong Lo, Alison B. Fleming, Roman V. Rariy
  • Patent number: 9833513
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: December 5, 2017
    Assignee: Eagle Biologics, Inc.
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Patent number: 9731026
    Abstract: Essentially non-aqueous liquid pharmaceutical formulations are formed by mixing at least one pharmaceutically active ingredient and at least one other compound capable of interacting with the active pharmaceutical ingredient through non-covalent interactions to form a low-temperature transition mixture. The stable liquid formulations are readily obtained, even with drugs that are poorly soluble and/or unstable in water.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: August 15, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Erzheng Su, Alexander M. Klibanov
  • Publication number: 20170182032
    Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In a preferred embodiment, a drug is modified to increase its lipophilicity. In some embodiments the modified drug is homogeneously dispersed within spherical microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and/or organic solvent insoluble. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.
    Type: Application
    Filed: March 13, 2017
    Publication date: June 29, 2017
    Inventors: Roman V. RARIY, Alison B. Fleming, Jane Hirsh, Alexander M. Klibanov
  • Patent number: 9592200
    Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In a preferred embodiment, a drug is modified to increase its lipophilicity. In some embodiments the modified drug is homogeneously dispersed within spherical microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and/or organic solvent insoluble. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: March 14, 2017
    Assignee: COLLEGIUM PHARMACEUTICAL, INC.
    Inventors: Roman V. Rariy, Alison B. Fleming, Jane Hirsh, Alexander M. Klibanov
  • Publication number: 20160143848
    Abstract: Essentially non-aqueous liquid pharmaceutical formulations are formed by mixing at least one pharmaceutically active ingredient and at least one other compound capable of interacting with the active pharmaceutical ingredient through non-covalent interactions to form a low-temperature transition mixture. The stable liquid formulations are readily obtained, even with drugs that are poorly soluble and/or unstable in water.
    Type: Application
    Filed: November 24, 2015
    Publication date: May 26, 2016
    Inventors: Erzheng Su, Alexander M. Klibanov